MedPath

Inspira Technologies Enhances HYLA Blood Sensor with AI-Powered Oxygenation Monitoring

• Inspira Technologies has integrated a next-generation oxygenation indicator into its HYLA blood sensor, enabling continuous monitoring of tissue oxygenation without blood draws.

• Clinical validation of the enhanced HYLA system is currently underway at Sheba Medical Center, with FDA submission planned for the second half of 2025.

• The technology aims to revolutionize the $2.5 billion point-of-care testing market by providing real-time monitoring of blood parameters and early detection of respiratory complications.

Inspira Technologies has announced a significant advancement in critical care monitoring with the integration of a next-generation oxygenation indicator into its AI-powered HYLA blood sensor technology. This enhancement enables healthcare providers to detect critical oxygen-related conditions without the need for traditional intermittent blood draws.

Advanced Monitoring Capabilities

The enhanced HYLA system utilizes sophisticated optical sensors and machine-learning algorithms to provide continuous, real-time monitoring of blood parameters and oxygen levels. This technology is specifically designed to detect tissue hypoxia and provide early warning of respiratory complications, representing a potential breakthrough in critical care monitoring.
"This advancement marks an important step in transforming critical care monitoring," said Dagi Ben-Noon, chief executive officer of Inspira. "The integration of this new oxygenation indicator into HYLA will enable healthcare providers to monitor and respond to changes in tissue oxygenation in real-time."

Clinical Validation and Regulatory Timeline

The enhanced HYLA blood sensor is currently undergoing clinical validation at Sheba Medical Center, ranked among the world's top 10 smart hospitals by Newsweek. The company expects to release preliminary clinical results in the near future, with plans to submit for FDA regulatory clearance in the second half of 2025.

Market Impact and Integration

The technology positions HYLA as a potential game-changer in the $2.5 billion point-of-care testing and arterial blood gas analyzer market. When integrated with the FDA-cleared INSPIRA ART100 system, it offers a comprehensive approach to patient care, particularly beneficial for the approximately 20 million intensive care unit patients with acute respiratory failure annually.

Technical Innovation

The non-invasive technology combines advanced optical sensing with AI-powered analytics to:
  • Monitor vital blood parameters continuously
  • Provide real-time tissue oxygenation data
  • Enable early detection of respiratory complications
  • Support informed clinical decision-making without blood draws
This technological advancement represents a significant step forward in critical care monitoring, offering healthcare providers a more efficient and less invasive method for tracking patient oxygenation levels and responding to changes in real-time.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Axcynsis Therapeutics' AT03-65 Receives FDA IND Clearance for CLDN6-Targeting ADC

Axcynsis Therapeutics received FDA clearance for its IND application for AT03-65, a differentiated CLDN6-targeting antibody-drug conjugate (ADC).
AT03-65 leverages Axcynsis' AxcynDOT™ technology for precise drug delivery to tumors expressing CLDN6, a target in various cancers.

Ignite Biomedical's AI-Driven TNFi Treatment Response Predictor Achieves Analytical Validation

Ignite Biomedical's Tumor Necrosis Factor-alpha Inhibitor (TNFi) Treatment Response Predictor (TRP) has achieved successful analytical validation, marking a key milestone in precision medicine.
The TNFi TRP utilizes RNA biomarkers identified through AI to predict patient response to TNF-alpha inhibitors, potentially transforming IBD patient care.

Omron's AI-Powered Atrial Fibrillation Detection Receives FDA Approval

Omron Healthcare secured FDA de novo authorization for its AI-powered atrial fibrillation (AFib) detection technology integrated into home blood pressure monitors.
The IntelliSense AFib algorithm analyzes pressure pulse waves during blood pressure measurements, demonstrating 95% sensitivity and 98% specificity in detecting AFib.

Intelligent Bio Solutions' Fingerprint Sweat Analysis Shows Promise in Drug Detection

Intelligent Bio Solutions (INBS) reported positive results from its Pharmacokinetic (PK) study, a crucial step toward FDA 510(k) submission.
The study demonstrated that fingerprint sweat effectively mirrors codeine levels in blood and saliva, validating its reliability for drug detection.

ExoStat Medical's MicroTREND System Receives FDA Clearance for Real-Time Oral Tissue Perfusion Monitoring

ExoStat Medical's MicroTREND system, designed for real-time detection of tissue hypoperfusion via oral mucosa, has received FDA 510(k) clearance.
The MicroTREND system utilizes an electro-conductance platform with a non-invasive sensor to measure pCO2, a marker for tissue hypoperfusion.

Movano Health Advances Cuffless Blood Pressure Monitoring with New Clinical Trial

Movano Health has initiated a clinical trial for its cuffless blood pressure wrist wearable, aiming to enhance data fidelity and reduce noise.
The study involves at least 70 participants and compares the wearable's pulse pressure waveforms against a hospital-grade blood pressure device.

HeartLung Technologies' AutoChamber AI Receives FDA Breakthrough Status for Opportunistic Heart Disease Detection

HeartLung Technologies' AutoChamber AI received FDA Breakthrough Device designation and marketing authorization for opportunistic heart disease detection in CT scans.
AutoChamber AI analyzes thoracic CT scans to evaluate the risk of heart failure, atrial fibrillation, and stroke, conditions often missed in current radiology reports.

Abbott Advances Pulsed Field Ablation with Study Milestones and New Cardiac Mapping Tech

Abbott completed enrollment in the VOLT-AF IDE study for its Volt PFA system ahead of schedule, marking progress in atrial fibrillation treatment.
The FOCALFLEX trial has been initiated to evaluate Abbott's TactiFlex Duo Ablation Catheter for paroxysmal atrial fibrillation using PFA and RF energy.

Intelligent Bio Solutions Progresses in FDA Approval Process for its COVID-19 Testing System

Intelligent Bio Solutions is advancing in the FDA approval process for its rapid COVID-19 testing system, potentially offering a new point-of-care diagnostic tool.
The company's system aims to provide quick and accurate results, addressing the ongoing need for accessible and efficient COVID-19 testing solutions.

Inspira Technologies Expands European Footprint with Innovimed Agreement for INSPIRA ART Clinical Trials

Inspira Technologies extends its service agreement with Innovimed Sp. z o.o to support clinical trials of INSPIRA ART medical devices across Europe.
The collaboration aims to navigate the EU's regulatory landscape, leveraging Innovimed's expertise for market entry in countries like Poland, Czech Republic, and Slovakia.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy